Format

Send to

Choose Destination
Mol Cancer Ther. 2012 Oct;11(10):2169-73. doi: 10.1158/1535-7163.MCT-12-0476-T. Epub 2012 Aug 3.

A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets.

Author information

1
Veterans Affairs Greater Los Angeles Health Care System, 161111 Plummer St., Sepulveda, CA 91343, USA. rweisbar@ucla.edu

Abstract

The therapeutic use of antibodies is restricted by the limited access of antibodies to intracellular compartments. To overcome this limitation, we developed a cell-penetrating monoclonal antibody, mAb 3E10, as an intracellular delivery vehicle for the intracellular and intranuclear delivery of antibodies constructed as bispecific single-chain Fv fragments. Because MDM2 is an important target in cancer therapy, we selected monoclonal antibody (mAb) 3G5 for intracellular transport. mAb 3G5 binds MDM2 and blocks binding of MDM2 to p53. Here, we show that the resulting 3E10-3G5 bispecific antibody retains cell-penetrating and MDM2-binding activity, increases tumor p53 levels, and inhibits growth of MDM2-addicted tumors. The use of cell-penetrating bispecific antibodies in targeted molecular therapy will significantly broaden the spectrum of accessible intracellular targets and may have a profound impact in cancer therapy.

PMID:
22863609
DOI:
10.1158/1535-7163.MCT-12-0476-T
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center